Bronchiectasis-Pipeline Review, H1 2017

Bronchiectasis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9292IDB
  • |
  • Pages: 71
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Bronchiectasis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis-Pipeline Review, H1 2017, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 5 and 2 respectively.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchiectasis-Overview

Bronchiectasis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bronchiectasis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchiectasis-Companies Involved in Therapeutics Development

Alitair Pharmaceuticals Inc

Bayer AG

Chiesi Farmaceutici SpA

GlaxoSmithKline Plc

Grifols SA

Insmed Inc

Kamada Ltd

Polyphor Ltd

Recipharm AB

Vertex Pharmaceuticals Inc

Bronchiectasis-Drug Profiles

alpha-1 proteinase inhibitor (human) second generation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amikacin sulfate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3150-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHF-6333-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ciprofloxacin hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doxofylline-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erdosteine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2269557-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INS-1007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-6014-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VX-371-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchiectasis-Dormant Projects

Bronchiectasis-Discontinued Products

Bronchiectasis-Product Development Milestones

Featured News & Press Releases

May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007

Dec 01, 2016: Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa

Oct 18, 2016: Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm Inhaled Ciprofloxacins

Oct 18, 2016: Bayer to Present Data in Non-Cystic Fibrosis Bronchiectasis at the 2016 Annual Meeting of the American College of Chest Physicians

Sep 22, 2016: Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients

Mar 17, 2016: Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency

Jan 05, 2016: Aradigm to Host Corporate Update Conference Call on January 6

Oct 13, 2015: Aradigm Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Sep 22, 2015: Aradigm Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)

Apr 16, 2015: Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City

Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia

Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation

Sep 04, 2014: FDA Grants Fast Track Designation to Aradigm's Pulmaquin for Non-Cystic Fibrosis Bronchiectasis

Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)

Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Bronchiectasis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Bronchiectasis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Bronchiectasis-Pipeline by Alitair Pharmaceuticals Inc, H1 2017

Bronchiectasis-Pipeline by Bayer AG, H1 2017

Bronchiectasis-Pipeline by Chiesi Farmaceutici SpA, H1 2017

Bronchiectasis-Pipeline by GlaxoSmithKline Plc, H1 2017

Bronchiectasis-Pipeline by Grifols SA, H1 2017

Bronchiectasis-Pipeline by Insmed Inc, H1 2017

Bronchiectasis-Pipeline by Kamada Ltd, H1 2017

Bronchiectasis-Pipeline by Polyphor Ltd, H1 2017

Bronchiectasis-Pipeline by Recipharm AB, H1 2017

Bronchiectasis-Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Bronchiectasis-Dormant Projects, H1 2017

Bronchiectasis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alitair Pharmaceuticals Inc, Bayer AG, Chiesi Farmaceutici SpA, GlaxoSmithKline Plc, Grifols SA, Insmed Inc, Kamada Ltd, Polyphor Ltd, Recipharm AB, Vertex Pharmaceuticals Inc

Bronchiectasis Therapeutic Products under Development, Key Players in Bronchiectasis Therapeutics, Bronchiectasis Pipeline Overview, Bronchiectasis Pipeline, Bronchiectasis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143120
Site License
USD 4000 INR 286240
Corporate User License
USD 6000 INR 429360

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com